Commercial insight into the pharma and biotech sector.

Forward-looking comment and analysis for pharma and biotech

EP Vantage is the forward-looking editorial comment and analysis service from EvaluatePharma with key opinion leader insight, tailored to the needs of pharma and finance professionals.

One of the key features of EvaluatePharma Alpha, EP Vantage focuses on the events that will define the future of companies, products and therapy areas.

Advanced intelligence
EP Vantage is integrated with the Calendar of Events, the Alpha service tracking tool, allowing coverage of potential market catalysts weeks and even months ahead of other industry sources.

Analysis and commentary on price-sensitive events
With analysis and commentary on price-sensitive events including regulatory decisions, product approvals, licensing deals, patent decisions and M&A. EP Vantage is powered by quantitative analysis from EvaluatePharma, the industry leader in product consensus forecasts.

Financial Insight
Additional insight into the financial impact of events is provided with the aid of Alpha's interactive NPV Analyzer, giving readers the full perspective and the insight to make value-enhancing decisions.

The highly experienced EP Vantage editorial team includes former Financial Times and Thomson Financial News journalists plus senior pharma analysts.

 

Subscriptions

EvaluatePharma® delivers unique commercial insight into the past and future performance of the pharma and biotech sector, in a user-friendly online subscription service.

Sign-up Now!